Processa Pharmaceuticals (PCSA) Free Cash Flow (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Free Cash Flow came in at -$3.6 million in Q1 2026, down 31.53% YoY from -$5.2 million in Q1 2025, and down 23.82% on a QoQ basis from -$2.9 million in Q4 2025.
Processa Pharmaceuticals (PCSA) Free Cash Flow (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Free Cash Flow data on file, last reported at -$3.6 million in Q1 2026.
- Quarterly Free Cash Flow fell 31.53% year-over-year to -$3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.3 million (down 2.81% YoY) and the FY2025 annual result came in at -$11.4 million, down 1.35% from the prior year.
- Free Cash Flow eased to -$3.6 million in Q1 2026, from -$2.9 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$1.8 million in Q3 2023 to a low of -$3.6 million in Q3 2024.
- A 5-year average of -$2.6 million and a median of -$2.3 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2023 — Free Cash Flow jumped 40.8% — and 2024, when it sank 104.58%.
- Tracing PCSA's Free Cash Flow over 5 years: stood at -$2.5 million in 2022, then climbed by 14.96% to -$2.1 million in 2023, then dropped by 5.83% to -$2.2 million in 2024, then slipped by 29.02% to -$2.9 million in 2025, then retreated by 23.82% to -$3.6 million in 2026.
- The last three Free Cash Flow figures came in at -$3.6 million (Q1 2026), -$2.9 million (Q4 2025), and -$3.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - | -1.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.59 Mn |
| Mar 31, 2026 | -3.59 Mn |
| Dec 31, 2025 | -2.90 Mn |
| Dec 31, 2025 | -2.90 Mn |
| Sep 30, 2025 | -3.50 Mn |
| Sep 30, 2025 | -3.50 Mn |
| Jun 30, 2025 | -2.27 Mn |
| Jun 30, 2025 | -2.27 Mn |
| Mar 31, 2025 | -2.73 Mn |
| Mar 31, 2025 | -2.73 Mn |
| Dec 31, 2024 | -2.25 Mn |
| Dec 31, 2024 | -2.25 Mn |
| Sep 30, 2024 | -3.60 Mn |
| Sep 30, 2024 | -3.60 Mn |
| Jun 30, 2024 | -3.35 Mn |
| Jun 30, 2024 | -3.35 Mn |
| Mar 31, 2024 | -2.05 Mn |
| Mar 31, 2024 | -2.05 Mn |
| Dec 31, 2023 | -2.12 Mn |
| Dec 31, 2023 | -2.12 Mn |